Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date22 Nov 2019 |
Real-world studies evaluate the effectiveness of Shujin Jianwaiwan in the treatment of lumbar disc herniation, Efficacy and safety of lumbar spinal stenosis and other pain disorders
/ Not yet recruitingPhase 4IIT Treatment of Kunxian Capsule for moderate to severe plaque psoriasis: a multi-center, randomized, double-blinded, double-dummy, positive-drug, parallel-controlled clinical trial
A multi-center, controlled, randomized, open-label clinical study on the efficacy and safety of Kunxian Capsule in the treatment of partially relieved lupus nephritis
100 Clinical Results associated with Guangzhou Chen Li Ji Pharmaceutical Factory Co. Ltd.
0 Patents (Medical) associated with Guangzhou Chen Li Ji Pharmaceutical Factory Co. Ltd.
100 Deals associated with Guangzhou Chen Li Ji Pharmaceutical Factory Co. Ltd.
100 Translational Medicine associated with Guangzhou Chen Li Ji Pharmaceutical Factory Co. Ltd.